Equities research analysts expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to post $0.47 earnings per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Integra LifeSciences Holdings Corporation’s earnings. The highest EPS estimate is $0.50 and the lowest is $0.46. Integra LifeSciences Holdings Corporation also posted earnings per share of $0.47 in the same quarter last year. The company is expected to report its next earnings report on Thursday, October 26th.

On average, analysts expect that Integra LifeSciences Holdings Corporation will report full year earnings of $1.90 per share for the current financial year, with EPS estimates ranging from $1.88 to $1.92. For the next financial year, analysts forecast that the firm will report earnings of $2.18 per share, with EPS estimates ranging from $2.13 to $2.32. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. The company had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The business’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same period last year, the business posted $0.40 earnings per share.

IART has been the topic of a number of recent analyst reports. Jefferies Group LLC boosted their price target on shares of Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Royal Bank Of Canada restated a “sector perform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, May 2nd. Oppenheimer Holdings, Inc. set a $54.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Monday, May 15th. ValuEngine downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Finally, UBS AG restated a “buy” rating and issued a $60.00 price target (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $52.63.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Integra LifeSciences Holdings Corporation (IART) to Announce $0.47 EPS” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/zacks-brokerages-anticipate-integra-lifesciences-holdings-corporation-iart-to-announce-0-47-eps.html.

In other Integra LifeSciences Holdings Corporation news, Director Stuart Essig sold 135,000 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the completion of the sale, the director now owns 2,077,475 shares in the company, valued at approximately $103,666,002.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were acquired at an average price of $49.25 per share, with a total value of $492,500.00. Following the purchase, the director now directly owns 29,612 shares in the company, valued at approximately $1,458,391. The disclosure for this purchase can be found here. Insiders have purchased a total of 17,550 shares of company stock worth $864,842 in the last quarter. 21.50% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after buying an additional 2,329,710 shares during the period. BlackRock Inc. raised its stake in shares of Integra LifeSciences Holdings Corporation by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock worth $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. raised its stake in shares of Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after buying an additional 3,046,488 shares during the period. Champlain Investment Partners LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock worth $187,005,000 after buying an additional 2,468,145 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Integra LifeSciences Holdings Corporation by 18.0% in the first quarter. Wells Fargo & Company MN now owns 2,467,892 shares of the life sciences company’s stock worth $103,972,000 after buying an additional 375,857 shares during the period. Institutional investors and hedge funds own 86.77% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (IART) traded down 1.19% during midday trading on Tuesday, hitting $49.89. 754,866 shares of the stock traded hands. The firm has a 50-day moving average price of $53.17 and a 200-day moving average price of $46.68. Integra LifeSciences Holdings Corporation has a 52 week low of $40.51 and a 52 week high of $88.86. The stock has a market capitalization of $3.90 billion, a P/E ratio of 60.84 and a beta of 0.73.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.